Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fawad Rizvi

Interventional Pain Medicine Farmington Hills, MI Doctor of Osteopathy

NPI 1700107349 CMS profile 259192

23800 Orchard Lake Rd Ste 200, Farmington Hills, MI 48336

Open in the dashboard

General payments

$16,105

664 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fawad Rizvi of Farmington Hills, MI is reported in the CMS Open Payments database as having received $16,105 across 664 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $420 20
2024 General $2,932 78
2023 General $2,833 85
2022 General $3,300 101
2021 General $2,234 141
2020 General $2,036 105
2019 General $2,349 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fawad Rizvi
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Fawad Rizvi were reported at $420. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Fawad Rizvi Interventional Pain Medicine median Middle half National median
2019 $2,349 $684 $216–$2,079 $163
2020 $2,036 $382 $122–$1,109 $114
2021 $2,234 $552 $167–$1,554 $132
2022 $3,300 $605 $187–$1,924 $149
2023 $2,833 $671 $195–$1,915 $160
2024 $2,932 $684 $206–$1,837 $164
2025 $420 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. IBSA Pharma Inc. $3,092 22 payments
  2. Boston Scientific Corporation $2,278 105 payments
  3. AbbVie, Inc. $1,444 86 payments
  4. Nevro Corp. $1,109 27 payments
  5. Collegium Pharmaceutical, Inc. $736 49 payments
  6. Scilex Pharmaceuticals Inc. $700 33 payments
  7. Allergan Inc. $646 44 payments
  8. Abbott Laboratories $559 8 payments
  9. Amgen Inc. $453 25 payments
  10. TerSera Therapeutics LLC $398 18 payments
  11. Other $4,692 247 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,302 658 payments
  2. Consulting Fee $2,300 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
  4. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. Licart $2,581 20 payments
  2. WaveWriter Alpha Prime 16 $1,120 39 payments
  3. Senza Spinal Cord Stimulation System $821 16 payments
  4. UBRELVY $688 38 payments
  5. Tirosint $620 8 payments
  6. AIMOVIG $578 34 payments
  7. BOTOX $566 37 payments
  8. Flector $551 4 payments
  9. ZTLido $509 21 payments
  10. QULIPTA $425 26 payments
  11. Other $9,655 524 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

227

Median for Anesthesiology: 322

Drug cost

$3,051

Median for Anesthesiology: $8,738

Branded share of claims

33%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 79 $1,181
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $627
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $552
Tizanidine Hcl Generic 28 $369
Amitriptyline Hcl Generic 16 $154
Methocarbamol Generic 15 $124
Cyclobenzaprine Hcl Generic 14 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$235,155

Of which drugs: $3,925

Medicare patients

442

Average age 71

Services billed

11,567

284 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Depression 36%
Ischemic heart disease 33%
Chronic kidney disease 28%
COPD 24%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 82 5,386 $528
Injection, methylprednisolone acetate, 40 mg J1030 Office 21 24 $106
Injection, propofol, 10 mg J2704 Office 30 495 $39
Injection, midazolam hydrochloride, per 1 mg J2250 Office 37 361 $36
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 66 117 $33
Injection, ketorolac tromethamine, per 15 mg J1885 Office 22 62 $31
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 11 31 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Licart
$620 — —
BELBUCA
$162 — —
BOTOX
$152 — —
Prialt
$115 — —
UBRELVY
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record